Company Overview and News
Integrated Device Technology, Inc. (IDTI - Free Report) has entered into a definitive agreement to collaborate with Thetasys, a California-based engineering company to enhance design and features of its sensor products by leveraging the latter’s inductive sensor designing capabilities. Thetasys is a developer of technology that aids in designing of sensor products and network applications. The collaboration will be operative in the United States and China.
CY FTV MLNX IDTI
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA
This week’s video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ - Free Report) , and International Paper (IP - Free Report) .
IP FTV JNJ INPAP ZBRA YY
Johnson & Johnson (JNJ - Free Report) has accepted a $2.1 billion offer from a private equity firm, Platinum Equity, for the sale of its LifeScan diabetes device unit. The company had announced the receipt of a binding offer from Platinum Equity in March.
FTV JNJ MDT
The Dow enjoyed a week of steady gains with trade concerns largely taking a backseat. Worries related to trade were only evident on Tuesday after Mexico imposed tariffs on a wide range of U.S. products. A spike in yields boosted financials on Wednesday. Tech stocks continued to make steady gains until investors indulged in profit-taking on Thursday.
GLW GIS MTSI UTX LB WMT TGT FTV JNJ MU AAPL MSFT UNH
Fortive Corporation (FTV - Free Report) has recently made a proposal to Johnson & Johnson (JNJ - Free Report) to acquire its business unit of Advanced Sterilization Products (“ASP”) from its subsidiary, Ethicon, Inc.. ASP offers infection prevention solutions that are used in disinfection and sterilization of reusable surgical instruments. The solutions are based on low-temperature hydrogen peroxide sterilization technology and help in protecting patients from hospital infections.
FTV JNJ AIMC TEL AME
Johnson & Johnson (JNJ - Free Report) announced that Fortive Corporation (FTV - Free Report) has offered to acquire its Advanced Sterilization Products (“ASP”) business, a unit of its surgical systems and instruments subsidiary Ethicon. Fortive has proposed a binding offer with an aggregate value of $2.8 billion for the unit. The offer comprises $2.7 billion in cash and $100 million in retained net receivables.
June 7 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1410 GMT on Thursday: ** Japan’s Fujifilm Holdings Corp said it may have no choice but to abandon a $6.1 billion merger with Xerox Corp if there is no progress in talks with the U.S. firm’s new board for about half a year. ** U.S. insurer AmTrust Financial Services Inc agreed to be acquired by a group of investors for a sweetened $2.
XOM MALRY AFSS AFST AFSI.PRC AFSI.PRB MIN FUJIF AFSI.PRA AFSI.PRF BOD AFSI.PRE AGO 4901 AFSI.PRD AGN AGN.PRA FMG VNRFY AGODY ACT VNRGF XRX FSUGY FTV FSUMF ATLGF 0700 MALRF AFSI FUJIY
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET